| Subselective intra-arterial chemotherapy infusion in the treatment of hepatocellular carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20494699 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Intra-arterial delivery of chemotherapy is a well-established dominant treatment for hepatocellular carcinoma (HCC). This approach takes advantage of differential blood supply to the cancer, which is arterial, and to the liver, which is predominantly portal. Randomized trials demonstrating survival benefit have used transarterial chemoembolization (TACE) with arrest of blood flow and arterial obstruction to increase efficiency of drug delivery. Treatment-associated morbidity is significant but usually justified by the patient benefit. A number of alternative embolic particles have been explored to address efficacy and toxicity deficiencies of the original technology. In this article we list those materials. We then develop evidence that sub-selective arterial infusion therapy without embolic agents provides equivalent efficacy with less treatment morbidity. |
| | |
Authors:
|
John R Daniels; Melissa Wallman |
Related Documents
:
|
3610509 - Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or ... 2956289 - Ischemic optic neuropathy secondary to intracarotid infusion of bcnu. 2579929 - Ventricular fibrillation. a complication and hazard of transcatheter obliteration of th... 9646779 - Interventional use of plasminogen activators in central nervous system diseases. 19685009 - Combined intraarterial and intravenous thrombolysis for severe cerebral venous sinus th... 7122749 - Vasospasm control by intra-arterial reserpine. 1935289 - Hypoxia and cyanosis in alpha-1-antitrypsin deficiency. cirrhosis as an unusual etiolog... 19371189 - Drug-eluting stents: a comprehensive appraisal. 18847339 - Direct percutaneous embolization of a carotid body tumor with onyx. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in oncology Volume: 37 ISSN: 1532-8708 ISO Abbreviation: Semin. Oncol. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-05-24 Completed Date: 2010-06-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0420432 Medline TA: Semin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 83-8 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Medicine, Division of Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Daniels@usc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage*,
adverse effects Carcinoma, Hepatocellular / drug therapy* Embolization, Therapeutic / methods Humans Infusions, Intra-Arterial* / methods Liver Neoplasms / drug therapy* Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cancer of unknown primary site.
Next Document: Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hep...